Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro

Thrombosis Research

Volumn 121, Issue 4, 2008, Pages 567-571

  Avcu, Ferit ^a   Ural, A Ugur ^a   Cetin, Turker ^a   Nevruz, Oral ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bortezomib; Platelet aggregation; Proteasome inhibitors

Indexed keywords

ADENOSINE TRIPHOSPHATE; BORTEZOMIB;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADENOSINE TRIPHOSPHATE; BLOOD PLATELETS; BORONIC ACIDS; HUMANS; NITRIC OXIDE; PLATELET AGGREGATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 38649099724     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.06.013     Document Type: Article

References (18)

1. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 Suppl 1 (2003) 3-9
2. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossat P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21 (2007) 30-36
3. Spano J.P., Bay J.O., Blay J.Y., and Rixe O. Proteasome inhibition: a new approach for the treatment of malignancies. Bull Cancer 92 (2005) 945-952
4. Caravita T., de Fabritiis P., Palumbo A., Amadori S., and Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 3 (2006) 374-387
5. Stangl V., Lorenz M., Meiners S., Ludwig A., Bartsch C., Moobel M., et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 18 (2004) 272-279
6. Zhang L., Zhang Z.G., Liu X., Hozeska A., Stagliano N., Riordan W., et al. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost 95 (2006) 166-173
7. Ostrowska J.K., Wojtukiewicz M.Z., Chabielska E., Buczko W., and Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost 92 (2004) 171-177
8. Ural A.U., Yilmaz M.I., Avcu F., and Yalcin A. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. Int J Hematol 76 (2002) 279-283
9. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8 (2001) 739-758
10. Ostrowska H., Ostrowska J.K., Worowski K., and Radziwon P. Human platelet 20S proteasome: inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report. Platelets 14 (2003) 151-157
11. Yukawa M., Sakon M., Kambayashi J., Shiba E., Kawasaki T., Ariyoshi H., et al. Proteasome and its novel endogeneous activator in human platelets. Biochem Biophys Res Commun 178 (1991) 256-262
12. Coux O., Tanaka K., and Goldberg A.L. Structure and function of the 20S and 26S proteasomes. Ann Rev Biochem 65 (1996) 801-847
13. Smith D.M., Benaroudj N., and Goldberg A. Proteasomes and their associated ATPases: a destructive combination. J Struct Biol 156 (2006) 72-83
14. Dosenko V.E., Zagorii VIu., and Moibenko A.A. Effect of proteasomal proteolysis on NO-synthase activity in isolated platelets. Ukr Biokhim Zh 77 (2005) 39-43
15. Willoughby S.R., Stewart S., Holmes A.S., Chirkov Y.Y., and Horowitz J.D. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Atherioscler Thromb Vasc Biol 25 (2005) 2661-2666
16. Bermejo E., Saenz D.A., Alberto F., Rosenstein R.E., Bari S.E., and Lazzari M.A. Effect of nitroxyl on human platelets function. Thromb Haemost 94 (2005) 578-584
17. Inhalation of nitric oxide inhibits ADP-induced platelet aggregation and alpha-granule release. Platelets 10 (1999) 382-390
18. Hechler B., Cattaneo M., and Gachet C. The P2 receptors in platelet function. Semin Thromb Haemost 31 (2005) 150-161